Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook

Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview

Metastatic castration-resistant prostate cancer (mCRPC) is an advanced, lethal malignancy defined by disease progression despite castrate levels of serum testosterone, driven by androgen receptor amplification, splice variants, or autonomous intra-tumoral steroidogenesis. It characteristically metastasizes to bone, regional lymph nodes, and visceral organs, presenting with bone pain, pathological fractures, spinal cord compression, and constitutional cachexia. Diagnosis integrates serial prostate-specific antigen tracking, bone scintigraphy, and advanced prostate-specific membrane antigen (PSMA) PET imaging, alongside mandatory genomic sequencing to identify actionable mutations. The 2026 therapeutic paradigm prioritizes biomarker-driven personalization over rigid sequencing, utilizing androgen receptor pathway inhibitors like abiraterone or enzalutamide, or taxane chemotherapies like docetaxel and cabazitaxel. For patients harboring homologous recombination repair alterations, particularly BRCA1 or BRCA2 mutations, frontline combination therapy pairing PARP inhibitors like talazoparib with enzalutamide has demonstrated definitive survival advantages. Furthermore, radioligand therapy with lutetium Lu 177 vipivotide tetraxetan is a standard of care for PSMA-positive disease following pathway inhibitor progression, while bone-targeted agents like denosumab are routinely added to lifelong androgen deprivation therapy to manage skeletal events and optimize survival.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036